Yang Y, Luo H, Zheng Y, Zou Z, Niu T, Jia Y
Ann Hematol. 2020; 100(1):135-141.
PMID: 33083863
DOI: 10.1007/s00277-020-04311-z.
Ma V, Boonstra P, Menghrajani K, Perkins C, Gowin K, Mesa R
Clin Lymphoma Myeloma Leuk. 2018; 18(5):e201-e210.
PMID: 29574002
PMC: 5927833.
DOI: 10.1016/j.clml.2018.02.019.
Gwaltney C, Paty J, Kwitkowski V, Mesa R, Dueck A, Papadopoulos E
Leuk Res. 2017; 59:26-31.
PMID: 28544906
PMC: 8207823.
DOI: 10.1016/j.leukres.2017.05.012.
Li B, Gale R, Xu Z, Qin T, Song Z, Zhang P
J Hematol Oncol. 2017; 10(1):99.
PMID: 28464892
PMC: 5414291.
DOI: 10.1186/s13045-017-0472-5.
Mascarenhas J, Talpaz M, Gupta V, Foltz L, Savona M, Paquette R
Haematologica. 2016; 102(2):327-335.
PMID: 27789678
PMC: 5286940.
DOI: 10.3324/haematol.2016.151126.
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.
Tefferi A, Al-Ali H, Barosi G, Devos T, Gisslinger H, Jiang Q
Leukemia. 2016; 31(4):896-902.
PMID: 27773929
PMC: 5383927.
DOI: 10.1038/leu.2016.300.
Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors.
Knight E, Osunsuyi-Fagbemi S, Neely J
J Adv Pract Oncol. 2016; 6(6):532-50.
PMID: 27648344
PMC: 5017545.
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.
Gupta V, Harrison C, Hexner E, Al-Ali H, Foltz L, Montgomery M
Haematologica. 2016; 101(12):e482-e484.
PMID: 27587385
PMC: 5479619.
DOI: 10.3324/haematol.2016.151449.
Ruxolitinib dose management as a key to long-term treatment success.
Mesa R, Komrokji R, Verstovsek S
Int J Hematol. 2016; 104(4):420-9.
PMID: 27567907
DOI: 10.1007/s12185-016-2084-1.
Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence.
Harrison C, Talpaz M, Mead A
Leuk Lymphoma. 2016; 57(10):2259-67.
PMID: 27463690
PMC: 4975083.
DOI: 10.1080/10428194.2016.1195501.
Which clinical significance has automatic detection of very low levels of nucleated red blood cells in the peripheral blood?.
Buoro S, Manenti B, Seghezzi M
Ann Transl Med. 2016; 4(11):230.
PMID: 27386496
PMC: 4916361.
DOI: 10.21037/atm.2016.05.50.
Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors.
Fauble V, Leis J, Mesa R
Leuk Suppl. 2016; 1(Suppl 1):S2-7.
PMID: 27175229
PMC: 4851182.
DOI: 10.1038/leusup.2012.2.
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.
Kroger N, Deeg J, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T
Leukemia. 2015; 29(11):2126-33.
PMID: 26293647
DOI: 10.1038/leu.2015.233.
Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis.
Barosi G, Rosti V, Gale R
Onco Targets Ther. 2015; 8:1091-102.
PMID: 26056473
PMC: 4445786.
DOI: 10.2147/OTT.S31916.
Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
Arana Yi C, Tam C, Verstovsek S
Future Oncol. 2015; 11(5):719-33.
PMID: 25757677
PMC: 4920055.
DOI: 10.2217/fon.14.272.
Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
Mesa R, Verstovsek S, Gupta V, Mascarenhas J, Atallah E, Burn T
Clin Lymphoma Myeloma Leuk. 2015; 15(4):214-221.e1.
PMID: 25682576
PMC: 4418454.
DOI: 10.1016/j.clml.2014.12.008.
A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis.
Oritani K, Okamoto S, Tauchi T, Saito S, Ohishi K, Handa H
Int J Hematol. 2015; 101(3):295-304.
PMID: 25638222
DOI: 10.1007/s12185-015-1746-8.
Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.
Shirane S, Araki M, Morishita S, Edahiro Y, Sunami Y, Hironaka Y
Int J Hematol. 2014; 101(2):148-53.
PMID: 25522845
DOI: 10.1007/s12185-014-1721-9.
Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.
Yacoub A, Odenike O, Verstovsek S
Curr Hematol Malig Rep. 2014; 9(4):350-9.
PMID: 25145552
PMC: 4223534.
DOI: 10.1007/s11899-014-0229-y.
Novel myelofibrosis treatment strategies: potential partners for combination therapies.
Stein B, Swords R, Hochhaus A, Giles F
Leukemia. 2014; 28(11):2139-47.
PMID: 24888274
DOI: 10.1038/leu.2014.176.
